Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
5-day change
1st Jan Change
42.12
USD
-0.40%
-1.98%
+18.38%
Sales 2024 *
1.5M
Sales 2025 *
27.9M
Capitalization
3.32B
Net income 2024 *
-245M
Net income 2025 *
-272M
EV / Sales 2024 *
1,864
x
Net cash position
2024
*
523M
Net cash position
2025
*
457M
EV / Sales 2025 *
103
x P/E ratio 2024 *
-12.8
x
P/E ratio 2025 *
-11.7
x
Employees
290
Yield 2024 *
-
Yield 2025 *
-
Free-Float
96.16%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Crinetics Pharmaceuticals Insider Sold Shares Worth $639,256, According to a Recent SEC Filing
Apr. 17
MT
Crinetics Pharmaceuticals Insider Sold Shares Worth $1,433,675, According to a Recent SEC Filing
Mar. 26
MT
Crinetics Pharmaceuticals Insider Sold Shares Worth $664,763, According to a Recent SEC Filing
Mar. 22
MT
Crinetics Pharmaceuticals Insider Sold Shares Worth $2,648,150, According to a Recent SEC Filing
Mar. 22
MT
Crinetics Pharmaceuticals Insider Sold Shares Worth $449,793, According to a Recent SEC Filing
Mar. 21
MT
JMP Securities Adjusts Price Target on Crinetics Pharmaceuticals to $80 From $60, Maintains Market Outperform Rating
Mar. 20
MT
Oppenheimer Raises Crinetics Pharmaceuticals Price Target to $55 From $54, Maintains Outperform Rating
Mar. 20
MT
JonesTrading Raises Crinetics Pharmaceuticals' Price Target to $56 From $52, Maintains Buy Rating
Mar. 20
MT
HC Wainwright Raises Crinetics Pharmaceuticals Price Target to $60 From $50, Maintains Buy Rating
Mar. 20
MT
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday
Mar. 19
MT
Correction: Crinetics Pharmaceuticals Says Phase 3 Trial for Acromegaly Treatment Meets Endpoints; Shares Rise Pre-Bell
Mar. 19
MT
Crinetics Pharmaceuticals Says Phase 3 Trial for Acromegaly Treatment Meets Endpoints; Shares Rise Pre-Bell
Mar. 19
MT
Transcript : Crinetics Pharmaceuticals, Inc. - Special Call
Mar. 19
Crinetics Pharma's hormonal disorder drug meets main goal in late-stage study
Mar. 19
RE
Crinetics Pharmaceuticals, Inc. Announces Positive Topline Results from PATHFNDR-2, Second of Two Phase 3 Studies Evaluating Efficacy and Safety of Oral, Once-Daily Investigational Paltusotine for Treatment of Acromegaly
Mar. 19
CI
More news
Crinetics Pharmaceuticals Insider Sold Shares Worth $639,256, According to a Recent SEC Filing
Apr. 17
MT
Crinetics Pharmaceuticals Insider Sold Shares Worth $664,763, According to a Recent SEC Filing
Mar. 22
MT
Crinetics Pharmaceuticals Insider Sold Shares Worth $2,648,150, According to a Recent SEC Filing
Mar. 22
MT
Crinetics Pharmaceuticals Insider Sold Shares Worth $449,793, According to a Recent SEC Filing
Mar. 21
MT
JMP Securities Adjusts Price Target on Crinetics Pharmaceuticals to $80 From $60, Maintains Market Outperform Rating
Mar. 20
MT
More recommendations
1 day -0.40%
1 week -1.98%
Current month -10.02%
1 month -2.88%
3 months +13.29%
6 months +44.15%
Current year +18.38%
More quotes
Managers
Title Age Since
Founder
58
07-12-31
Founder
62
07-12-31
Director of Finance/CFO
45
17-12-31
Members of the board
Title Age Since
Chairman
76
15-09-30
Director/Board Member
59
18-01-31
Director/Board Member
71
20-09-02
More insiders
Date
Price
Change
Volume
24-04-26
42.12
-0.40%
563,205
24-04-25
42.29
-2.38%
591,321
24-04-24
43.32
-2.04%
485,697
24-04-23
44.22
+1.80%
612,462
24-04-22
43.44
+1.09%
465,271
Delayed Quote
Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotes
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its Paltusotine, an investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. It has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894, an investigational, oral ACTH antagonist, that is in Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing's disease. Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
More about the company
Last Close Price
42.29
USD
Average target price
57.23
USD
Spread / Average Target
+35.33%
Consensus
1st Jan change
Capi.
+18.38% 3.3B +1.51% 42.59B +8.57% 40.65B +49.22% 40.57B -12.36% 26.77B +8.92% 24.81B -25.13% 18.17B +29.17% 12.05B -3.12% 11.7B +6.35% 11.1B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1